Art…you make some compelling points, but, there are two things that need attention.
The first is the upcoming NOPAIN Act. What you’re missing imo is that this legislation has considerably changed the intrinsic potential value for BIEL. Politics/lobbying, and a wild money spigot should insurance coverage happen via CMS.
The second thing, “What is past is prologue” - that the past/history sets the context for BIEL’s current worth, is now irrelevant given the Act. The history of BIEL does not set the context for its value for other companies/suitors of means and muscle. Furthermore, as time moves on towards implementation of the NOPAIN Act, that worth increases. The further fuel on the fire is the “coincidences” of VLMX, Viant, etc. Who else? Unknown.
What company or two or three of considerable means will make a move, if not already?
BIEL’s wearable PSWT technology is potentially disruptive in and of itself. And now it is additionally potentially disruptive given the NOPAIN Act and possible CMS reimbursement.
One thing all potential suitors love is money, and this Congress-passed Bill with possible insurance reimbursement should be on the radar of many.
Again, BIEL is worth a measured investment. I believe “objects in the mirror are closer than they appear”. One should not look at that mirror to see where one has been, but for what is coming up.
BIEL has the goods and FDA clearances.
It’s turnkey.
Perspective.
All imo.
